Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Return on Capital Employed (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Return on Capital Employed data on record, last reported at 0.43% in Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 52.0% year-over-year to 0.43%; the TTM value through Dec 2025 reached 0.43%, down 52.0%, while the annual FY2025 figure was 0.37%, 47.0% down from the prior year.
  • Return on Capital Employed reached 0.43% in Q4 2025 per TRDA's latest filing, down from 0.3% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.2% in Q2 2024 and bottomed at 0.43% in Q4 2025.
  • Average Return on Capital Employed over 4 years is 0.12%, with a median of 0.1% recorded in 2023.
  • Peak YoY movement for Return on Capital Employed: skyrocketed 45bps in 2024, then crashed -52bps in 2025.
  • A 4-year view of Return on Capital Employed shows it stood at 0.4% in 2022, then soared by 98bps to 0.01% in 2023, then soared by 1045bps to 0.09% in 2024, then crashed by -554bps to 0.43% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 0.43% in Q4 2025, 0.3% in Q3 2025, and 0.21% in Q2 2025.